Empagliflozin to Treat Heart Failure With Preserved Ejection Fraction
hosted byConnect Educate Impact (CEI)
Empagliflozin to Treat Heart Failure With Preserved Ejection Fraction is organized by Connect Educate Impact (CEI).
Initial Release Date: September 14, 2022
Planned Expiration Date: September 14, 2025
Description:
Heart failure with preserved ejection fraction (HFpEF) accounts for 50% of chronic heart failure cases, and effective therapies have been limited. This course reviews the EMPEROR-PRESERVED Trial and discusses whether or not the use of empagliflozin on heart failure in patients with HFpEF provides positive outcomes.
Objectives:
Upon successful completion of this application-based course, participants should be able to:
• Summarize current heart failure management strategies and guidelines
• Describe the use of SGLT2i's in heart failure management
• Interpret the results of the EMPEROR-PRESERVED Trial
• Discuss the validity of the EMPEROR-PRESERVED Trial
• Apply the EMPEROR-PRESERVED Trial results to a patient case
